Lee Jin Seo, Park So Yeon, Kim Jae Seok, You Ji Young, Ju Young-Su, Eom Joong Sik
Department of Internal Medicine, Division of Infectious Disease, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
Scand J Infect Dis. 2012 Aug;44(8):595-9. doi: 10.3109/00365548.2011.652161. Epub 2012 Apr 12.
Oseltamivir is widely used for the treatment of influenza infection, but data on its effectiveness in treating infections with pandemic influenza A H1N1 2009 are scarce. Therefore, we compared the effectiveness of oseltamivir and routine symptomatic treatment in pandemic influenza A H1N1 2009 infection.
Between August and October 2009, among laboratory confirmed influenza cases who were aged over 15 y with no underlying disease, 90 patients with oseltamivir treatment and 72 patients with symptomatic treatment were evaluated by telephone interviews to compare clinical outcomes. No patient was hospitalized. The primary end-point was the duration of illness. We also assessed the time to attain a sense of well-being and the time to return to normal activity.
There was no statistically significant difference in the duration of illness between the oseltamivir-treated group and the symptomatic treatment group (mean duration after the start of treatment, 6.50 ± 3.75 days vs 7.04 ± 3.75 days). There was also no statistically significant difference between the 2 groups in the time to a sense of well-being (1.70 ± 1.57 days vs 2.00 ± 2.12 days) and to return to normal activity (7.13 ± 2.61 days vs 7.58 ± 2.71 days). The complication rate was very low (only 2 cases of mild pneumonia in oseltamivir recipients) and no significant difference was found between the 2 groups (p = 0.50).
Oral oseltamivir treatment does not significantly reduce the duration of illness or influenza-related complications in mild pandemic influenza A H1N1 2009 virus infection in previously healthy adults.
奥司他韦被广泛用于治疗流感感染，但关于其治疗2009年甲型H1N1大流行性流感感染有效性的数据却很稀少。因此，我们比较了奥司他韦与常规对症治疗对2009年甲型H1N1大流行性流感感染的有效性。
在2009年8月至10月期间，对年龄超过15岁且无基础疾病的实验室确诊流感病例进行研究，通过电话访谈对90例接受奥司他韦治疗的患者和72例接受对症治疗的患者进行评估，以比较临床结局。所有患者均未住院。主要终点为疾病持续时间。我们还评估了恢复良好感觉的时间以及恢复正常活动的时间。
奥司他韦治疗组与对症治疗组在疾病持续时间上无统计学显著差异（治疗开始后的平均持续时间，分别为6.50±3.75天和7.04±3.75天）。两组在恢复良好感觉的时间（分别为1.70±1.57天和2.00±2.12天）以及恢复正常活动的时间（分别为7.13±2.61天和7.58±2.71天）上也无统计学显著差异。并发症发生率非常低（奥司他韦治疗者中仅2例轻度肺炎），两组之间未发现显著差异（p = 0.50）。
对于先前健康的成年人，口服奥司他韦治疗并不能显著缩短2009年甲型H1N1大流行性流感轻症感染的疾病持续时间或减少流感相关并发症。
